James Condulis
Stock Analyst at Stifel Nicolaus
(4.14)
# 1,547
Out of 4,476 analysts
44
Total ratings
68.4%
Success rate
18.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics | Downgraded: Hold | $25 → $3 | $3.84 | -21.88% | 5 | Jun 2, 2026 | |
| EWTX Edgewise Therapeutics | Maintained: Hold | n/a | $39.56 | - | 5 | Jun 1, 2026 | |
| TECX Tectonic Therapeutic | Maintained: Buy | $75 | $37.93 | +97.73% | 2 | May 8, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $130 → $136 | $125.59 | +8.29% | 7 | May 7, 2026 | |
| CYTK Cytokinetics | Rated: Buy | $98 → $108 | $86.49 | +24.87% | 15 | May 6, 2026 | |
| AMLX Amylyx Pharmaceuticals | Initiated Coverage: Buy | $21 | $18.27 | +14.94% | 1 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgraded: Hold | $24 → $6 | $5.70 | +5.26% | 4 | Mar 2, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintained: Buy | $50 | $34.83 | +43.55% | 4 | Feb 6, 2026 | |
| XFOR X4 Pharmaceuticals | Initiated Coverage: Buy | $10 | $4.13 | +142.13% | 1 | Dec 5, 2025 |
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $25 → $3
Current: $3.84
Upside: -21.88%
Edgewise Therapeutics
Jun 1, 2026
Maintained: Hold
Price Target: n/a
Current: $39.56
Upside: -
Tectonic Therapeutic
May 8, 2026
Maintained: Buy
Price Target: $75
Current: $37.93
Upside: +97.73%
Mirum Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $130 → $136
Current: $125.59
Upside: +8.29%
Cytokinetics
May 6, 2026
Rated: Buy
Price Target: $98 → $108
Current: $86.49
Upside: +24.87%
Amylyx Pharmaceuticals
Mar 3, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $18.27
Upside: +14.94%
Aardvark Therapeutics
Mar 2, 2026
Downgraded: Hold
Price Target: $24 → $6
Current: $5.70
Upside: +5.26%
NewAmsterdam Pharma Company
Feb 6, 2026
Maintained: Buy
Price Target: $50
Current: $34.83
Upside: +43.55%
X4 Pharmaceuticals
Dec 5, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $4.13
Upside: +142.13%